Principal Financial Group’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-14,724
Closed -$57.7K – 2346
2024
Q2
$57.7K Sell
14,724
-11,660
-44% -$50.2K ﹤0.01% 2267
2024
Q1
$111K Sell
26,384
-2,056
-7% -$9.65K ﹤0.01% 2259
2023
Q4
$134K Sell
28,440
-2,043
-7% -$7.95K ﹤0.01% 2228
2023
Q3
$95.1K Buy
30,483
+2,780
+10% +$11.2K ﹤0.01% 2293
2023
Q2
$127K Buy
27,703
+1,758
+7% +$8.08K ﹤0.01% 2253
2023
Q1
$128K Buy
25,945
+3,359
+15% +$16.5K ﹤0.01% 2259
2022
Q4
$123K Buy
+22,586
New +$139K ﹤0.01% 2269
2022
Q2
– Sell
-13,753
Closed -$96K – 2603
2022
Q1
$96K Buy
13,753
+778
+6% +$5.31K ﹤0.01% 2431
2021
Q4
$132K Buy
+12,975
New +$139K ﹤0.01% 2417

Other funds holding MXCT

Principal Financial Group's MXCT Position: Q3 2024 in Review

Principal Financial Group sold out of MaxCyte (MXCT) in Q3 2024, closing a stake of 14,724 shares — an estimated $57.7K sold.

Principal Financial Group first reported a position in MXCT in Q4 2021 and held it in 9 quarters. The position peaked at $134K in Q4 2023. 120 funds tracked by Wall St. Rank hold MXCT as of Q3 2024.

  • Principal Financial Group reported no remaining MaxCyte position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 14,724 MaxCyte shares in Q3 2024, an estimated $57.7K.
  • Principal Financial Group first reported a position in MaxCyte in Q4 2021 and held it in 9 quarters.
  • Principal Financial Group's MaxCyte position peaked at $134K in Q4 2023.
  • 120 funds tracked by Wall St. Rank held MaxCyte as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.